Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Prog Neurobiol. 2023 May 4;226:102460. doi: 10.1016/j.pneurobio.2023.102460

Figure 1: Corrected motor function and normalized neuropathology after ASPA re-expression in neonatal and juvenile mice.

Figure 1:

(A) Timeline of single rAAV administration per age group and their corresponding motor testing ages. Wildtype (WT), no injection Nur7 (UT), and injected Nur7 mice at either neonatal (Neo) or juvenile (Juv) ages were tested four weeks post the ASPA re-expression timepoint and at additional timepoints up to one year of age. (B) Accelerated rotarod and (C) balance beam motor testing of all experimental groups (n=9-10 each) up to one year of age (52 weeks). (D) MRI T2 sequences of coronal brain sections (hyper-intensive areas marked by dashed red line) and (E) hematoxylin and eosin (H&E) staining of brain regions at one year of age. CTX/STR: cortex/striatum; HIP/TH: hippocampus/thalamus; MB: midbrain; CB/PON: cerebellum/pons. One-way ANOVA with multi-comparison correction, mean ±SD, ns = not significant, * p<0.05; ** p<0.01, *** p<0.001, **** p<0.0001.